MASCOLO, ANNAMARIA
 Distribuzione geografica
Continente #
AS - Asia 1.320
NA - Nord America 628
SA - Sud America 551
EU - Europa 369
Continente sconosciuto - Info sul continente non disponibili 95
AF - Africa 39
OC - Oceania 3
Totale 3.005
Nazione #
US - Stati Uniti d'America 562
BR - Brasile 430
SG - Singapore 312
VN - Vietnam 264
CN - Cina 225
HK - Hong Kong 177
BD - Bangladesh 144
IT - Italia 116
DE - Germania 97
KR - Corea 97
FR - Francia 61
AR - Argentina 55
CA - Canada 28
ID - Indonesia 26
EC - Ecuador 22
GB - Regno Unito 21
IN - India 17
CO - Colombia 16
MX - Messico 15
ZA - Sudafrica 13
RU - Federazione Russa 12
UA - Ucraina 12
IQ - Iraq 10
NL - Olanda 10
PL - Polonia 10
MA - Marocco 9
PE - Perù 8
PY - Paraguay 8
CR - Costa Rica 7
EG - Egitto 6
TN - Tunisia 6
UZ - Uzbekistan 6
CL - Cile 5
KZ - Kazakistan 4
NP - Nepal 4
TR - Turchia 4
AU - Australia 3
AZ - Azerbaigian 3
BG - Bulgaria 3
ES - Italia 3
JM - Giamaica 3
JO - Giordania 3
JP - Giappone 3
KE - Kenya 3
PH - Filippine 3
PK - Pakistan 3
PR - Porto Rico 3
SA - Arabia Saudita 3
SE - Svezia 3
TH - Thailandia 3
UY - Uruguay 3
VE - Venezuela 3
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
FI - Finlandia 2
GE - Georgia 2
GT - Guatemala 2
PT - Portogallo 2
RO - Romania 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AT - Austria 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
BO - Bolivia 1
CH - Svizzera 1
GR - Grecia 1
HT - Haiti 1
HU - Ungheria 1
IE - Irlanda 1
IR - Iran 1
KW - Kuwait 1
MK - Macedonia 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
Totale 2.912
Città #
Hong Kong 177
Seoul 97
Singapore 91
Frankfurt am Main 82
Ho Chi Minh City 80
Ashburn 70
Beijing 56
Hanoi 54
Chicago 49
Council Bluffs 41
São Paulo 40
New York 29
Los Angeles 25
San Jose 23
Santa Clara 23
Hillsboro 19
Dallas 15
Milan 13
Curitiba 12
Da Nang 11
Haiphong 11
Rio de Janeiro 11
Munich 10
Princeton 10
Toronto 10
Brooklyn 9
Rome 9
Abbeville 8
Belo Horizonte 8
Brasília 8
Porto Alegre 8
Quito 8
Thái Bình 8
Warsaw 8
Biên Hòa 7
Guayaquil 7
London 7
Ha Long 6
Hải Dương 6
Mexico City 6
Recife 6
Salvador 6
Baghdad 5
Bexley 5
Buenos Aires 5
Campinas 5
Can Tho 5
Jakarta 5
Juiz de Fora 5
Lima 5
Naples 5
Ninh Bình 5
San José 5
Florence 4
Montreal 4
Nova Iguaçu 4
Novo Hamburgo 4
Sumaré 4
Tashkent 4
Thái Nguyên 4
Amman 3
Amsterdam 3
Asunción 3
Aversa 3
Baku 3
Bandung 3
Barbacena 3
Belém 3
Bogotá 3
Bologna 3
Buffalo 3
Bắc Ninh 3
Camaçari 3
Campos dos Goytacazes 3
Cape Town 3
Cariacica 3
Catania 3
Chennai 3
Cotia 3
Fortaleza 3
Joinville 3
Karbala 3
Las Vegas 3
Madrid 3
Montes Claros 3
Nairobi 3
Nha Trang 3
Osasco 3
Philadelphia 3
Phoenix 3
Phủ Lý 3
Resistencia 3
Roubaix 3
Santo André 3
Serra 3
Sofia 3
Sorocaba 3
St Petersburg 3
Stockholm 3
São José do Rio Preto 3
Totale 1.387
Nome #
Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database 136
The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis 64
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta‐blocker use: a Danish nationwide cohort study 62
Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database 61
Risk of Rhabdomyolysis Associated with Dexmedetomidine Use over the Past 10 Years: Insights from the EudraVigilance Database 60
Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance 57
Current and future therapeutic perspective in chronic heart failure 57
Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials 54
PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database 53
Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database 52
COVID-19 Vaccines and Atrial Fibrillation: Analysis of the Post-Marketing Pharmacovigilance European Database 51
Facts and figures of the compassionate use of onco-hematological drugs from 2016 to 2021: Results from the multicentric observational study Compass-O 50
T-cell malignancies following CAR T-Cell therapy: insights from the FDA Adverse Event Reporting System (FAERS) 50
Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study 49
Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL 48
Hypernatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database 47
Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database 47
Angiotensin II and angiotensin 1–7: which is their role in atrial fibrillation? 45
The Early Access and the Potential Cost Savings by the Compassionate Use of Onco-haematological Drugs: Results from the Italian Study Compass-O 44
Neutral endopeptidase (neprilysin) 44
Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting 44
The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study 43
Endotoxin: Structure Source and Effects 42
Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study 42
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance 41
Preliminary results of the FASM study, an on-going italian active pharmacovigilance project 41
The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19 41
European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events 40
Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System 40
Correction to: Angiotensin II and angiotensin 1–7: which is their role in atrial fibrillation? 40
Thromboembolic Events after COVID-19 Vaccination: An Italian Retrospective Real-World Safety Study 39
Antipsychotics and Cardiac Side Effects 39
Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database 38
Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review 38
Quinolones-Induced Musculoskeletal, Neurological, and Psychiatric ADRs: A Pharmacovigilance Study Based on Data From the Italian Spontaneous Reporting System 38
Response to the comment on “SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies” 37
Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy 37
Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase® 37
Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study 37
Contribution of Italian Clinical Research for Contrast Media-Induced Nonrenal Adverse Drug Reactions over the Last Three Decades: A Systematic Review 36
New and old roles of the peripheral and brain renin–angiotensin–aldosterone system (RAAS): Focus on cardiovascular and neurological diseases 36
Do immune checkpoint inhibitors share the same pharmacological feature in the risk of cardiac arrhythmias? 36
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary 36
The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study 36
Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases 36
Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System 35
The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine 35
Contribution of Italian clinical research for contrast media-induced nonrenal adverse drug reactions over the last three decades: A systematic review 35
Decolonization of drug-resistant Enterobacteriaceae carriers: A scoping review of the literature 34
A case of figurate urticaria by etanercept 34
Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study 33
Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug Reactions 32
Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System 32
Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs 32
SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies 31
Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19 31
The efficacy and the safety of Eltrombopag in pediatric patients with Severe Aplastic Anemia: a systematic review 31
Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions 30
Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting syste 30
What Is the Role of Nutraceutical Products in Cancer Patients? A Systematic Review of Randomized Clinical Trials 30
Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different β1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study 30
Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis 30
Therapeutic strategies to fight COVID‐19: Which is the status artis? 29
Relationship Between Gender and the Effectiveness of Montelukast: An Italian/Danish Register-Based Retrospective Cohort Study 29
Pillars and Pitfalls of the New Pharmacovigilance legislation: Consequences for the identification of adverse drug reactions deriving from abuse, misuse, overdose, occupational exposure, and medication errors 28
Response to the comment “Is SGLT2i superior to DPP4i for primary and secondary prevention of cardiovascular diseases and death in patients with type 2 diabetes?” 28
The pathophysiological role of natriuretic peptide-RAAS cross talk in heart failure 28
Suspected adverse reactions to contrast media in Campania Region (Italy): Results from 14 years of post-marketing surveillance 27
Contrast media-induced nephropathy: how has Italy contributed in the past 30 years? A systematic review 27
The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs 26
Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system? 24
Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance 24
New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs) 23
Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article 22
Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data 18
Immune checkpoint inhibitors and metabolic events: results from a European safety analysis 13
Semaglutide Exposure During Pregnancy: Results from the FAERS Database 7
Safety profile of fentanyl with different routes of administration: a disproportionality analysis using the EudraVigilance database 6
Totale 3.005
Categoria #
all - tutte 21.332
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.332


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025463 0 0 0 6 84 107 40 30 35 23 112 26
2025/20262.275 119 143 368 519 196 55 45 153 167 235 170 105
2026/2027267 61 77 33 96 0 0 0 0 0 0 0 0
Totale 3.005